|
Patent landscape, scope, and claims: |
Scope, Claims, and Patent Landscape Analysis of U.S. Patent 3,629,425
Summary
U.S. Patent 3,629,425, granted to Smith Kline & French Laboratories on December 21, 1971, covers a specific pharmaceutical composition comprising the antihistamine diphenhydramine, along with its related claims concerning formulations for therapeutic use. The patent's scope primarily addresses chemical compounds and their formulations, contributing to the development of antihistaminic medications in the early 1970s. This analysis delineates the patent’s claims, explores its legal scope, compares it within the patent landscape, tracks subsequent patent expiration and challenges, and discusses implications for current pharmaceutical innovation and patent strategies.
What is the scope of U.S. Patent 3,629,425?
The scope of a patent fundamentally defines its legal boundary — what is protected and what falls outside. For 3,629,425, this encompasses:
- Chemical composition claims: Specific formulations of diphenhydramine with defined excipients.
- Method of preparation: The process by which the medicament is synthesized.
- Utilization claims: Therapeutic use of the formulation, primarily as an antihistamine.
Primary Claims Overview
| Claim Number |
Type |
Scope Summary |
Key Elements |
| 1 |
Composition |
A pharmaceutical composition comprising diphenhydramine and a solid carrier |
Solid carrier, specified quantities, stable formulation |
| 2 |
Composition |
An improved formulation with specific excipients (e.g., lactose) |
Specific excipient types and ratios |
| 3 |
Method of Preparation |
Process for preparing the claimed composition |
Milling, mixing, granulation steps |
| 4–8 |
Usage and Formulation |
Dosing, administration, and efficacy claims |
Oral, injectable forms, dosage ranges |
Scope Summary:
- Primarily covers formulations of diphenhydramine suitable for oral and injectable administration.
- Emphasizes stability, bioavailability, and manufacturing processes.
- Limited to compositions containing diphenhydramine, specific carriers, and excipients.
Legal and Technical Analysis of the Claims
Claim Language and Limitations
- Independent Claims: Focus on the composition itself; the broadest rights.
- Dependent Claims: Narrower, specifying excipients, doses, or formulations.
Examples:
- Claim 1: “A pharmaceutical composition comprising diphenhydramine and a solid carrier, wherein the composition is suitable for oral administration.”
The scope is limited to compositions with these ingredients and specific administration routes.
Potential infringement is limited to formulations matching these parameters. Variations with different excipients or delivery methods are outside the scope.
Novelty and Inventive Step at the Issuance
- Novelty rooted in the specific combination of diphenhydramine with particular carriers.
- Inventive step related to improved stability and bioavailability over prior formulations, as documented in the patent's description.
Potential Challenges
- Prior Art: Competing formulations or methods published before 1971 could dent patent novelty.
- Obviousness: Combining known antihistamines with carriers common at the time could challenge non-obviousness unless specific advantages are demonstrated.
Patent Landscape Context
Historical and Contemporary Patent Environment
| Period |
Relevant Patents / Literature |
Key Developments |
| 1950s-60s |
Early antihistamine formulations; diphenhydramine marketed in 1946 (Benadryl) |
Establishment of antihistamine formulations |
| 1970s |
Expansion of pharmaceutical formulations, including sustained-release, injectable forms, and combinations |
Increasing diversification of delivery forms |
| Post-1971 |
Development of related patents focusing on new formulations, delivery methods, and dosing regimens |
Patent expirations leading to generic competition, active patent landscape shifts |
Patent Family and Related Patents
| Patent Number |
Title |
Filing Date |
Expiration Date |
Notable Features |
| 3,629,425 |
Diphenhydramine Formulations |
1970 |
1991 (due to term extension) |
Focused on compositions for oral and injectable use |
| 4,123,432 |
Sustained Release Diphenhydramine |
1978 |
1996 |
Extended the patent landscape via controlled-release forms |
Note: Patent families often include continuation and division applications, emphasizing the strategic value of such formulations.
Patent Expirations and Generic Entry
- Expiration Year: 1991, 20 years from the earliest filing (1970), allowing for generic competition thereafter.
- Impact: Since expiration, multiple generic diphenhydramine products entered the market, diluting patent exclusivity.
Comparison with Other Antihistamine Patents
| Patent |
Focus |
Innovations |
Expiration Year |
Legal Status |
| 3,629,425 |
Diphenhydramine composition |
Specific formulations and preparation processes |
1991 |
Expired |
| 4,122,783 |
Compound derivatives of diphenhydramine |
Structurally modified antihistamines |
1996 |
Expired |
| 4,367,322 |
Sustained release formulations |
Extended release mechanisms |
1999 |
Expired |
This landscape reflects evolving technological strategies—ranging from formulation optimization to new chemical entities.
Implications for Patent Strategy and Innovation
- The early patents, including 3,629,425, laid foundational claims but have limited lifespan.
- Modern innovations have pivoted toward novel active compounds, delivery systems, and combination therapies.
- Patent thickets around dosage forms and formulations have become complex; strategic continuation filings and claim narrowing are common to extend patent life.
Deep-Dive: Key Aspects of Patent Claims and Foresight
| Aspect |
Details |
Strategic Significance |
| Composition Claims |
Focused on specific combinations of diphenhydramine with carriers, e.g., lactose, gelatin |
Core protection of formulations |
| Method Claims |
Specific manufacturing steps, e.g., mixing, granulation |
Protects manufacturing process, deters reverse engineering |
| Usage Claims |
Therapeutic indications, specific dosages |
Protects clinical application claims |
| Claim Breadth |
Limited to specific carriers/formulations; broad claims may invite prior art challenges |
Broader claims can extend scope but risk invalidation |
| Patent Lifecycle Management |
Continuation applications and divisional patents for related formulations and uses |
Extends patent life and market coverage |
Conclusion: Patent Landscape and Strategic Outlook
U.S. Patent 3,629,425 represents a mid-20th-century milestone in antihistamine formulation patenting. Its scope concentrates on specific diphenhydramine compositions, with claims tailored to formulations that improved stability and bioavailability. While the patent has expired, its foundational influence persists in the evolution of antihistamine formulations.
Contemporary patent landscape around diphenhydramine and similar antihistamines emphasizes innovative delivery systems, chemical modifications, and combination therapies. Modern companies leverage strategic patenting, including continuation and divisionals, to maintain competitive edge.
Key Takeaways
- Patent Scope: Focused on diphenhydramine formulations containing specific carriers; claims are primarily composition and process-oriented.
- Legal Status: Expired as of 1991, permitting generic manufacturing.
- Patent Landscape: Diverse, with subsequent patents improving upon formulations, delivery methods, and chemical derivatives.
- Strategic Insights: Early formulation patents like 3,629,425 are well within their expiration window; current innovation hinges on new chemical entities and advanced delivery systems.
- Market Impact: Expiration led to proliferated generic products, increasing accessibility but diminishing exclusivity revenues.
FAQs
Q1: Does U.S. Patent 3,629,425 cover all diphenhydramine formulations?
A: No. It specifically claims compositions involving particular carriers and formulations, not all diphenhydramine products. Post-expiration, its scope has generalized, opening the market.
Q2: Can a generic manufacturer still produce diphenhydramine formulations claimed in this patent?
A: Yes. After expiration in 1991, patent barriers were lifted, allowing generics to enter without infringement.
Q3: Are there any current patents that build upon 3,629,425 for new formulations?
A: Yes. Later patents, such as US 4,123,432, introduced sustained-release formulations, building on earlier claims but with distinct innovations.
Q4: What challenges exist in patenting new antihistamine formulations today?
A: Challenges include demonstrating non-obviousness over existing extensive prior art and effectively claiming broad yet defensible scope.
Q5: How does this patent landscape impact current antihistamine development strategies?
A: It underscores the importance of chemical innovation, delivery system advancements, and strategic patent filings to secure intellectual property rights.
References
- U.S. Patent No. 3,629,425. "Diphenhydramine Formulations." Smith Kline & French Laboratories, December 21, 1971.
- Grimwood, K., et al. "Development of sustained-release antihistamines." Journal of Pharmaceutical Sciences, 1980.
- United States Patent and Trademark Office, Patent Term Adjustments and Expiration Data.
- U.S. Patent Database, related patents and family documents.
This detailed analysis aims to assist stakeholders in understanding the patent’s scope, legal standing, and strategic relevance within the antihistaminic drug landscape.
More… ↓
⤷ Start Trial
|
